Physician

Ahmet Sevimli, MD

According to 2025 Medicare claims, Ahmet Sevimli, MD (NPI: 1912096629) practices nephrology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is FLORIDA KIDNEY AND HYPERTENSION SPECIALISTS PA (NPI: 1952557860; TIN: 26-3093773) and primary practice location at 32763-8468.

Sevimli's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 660 traditional Medicare patients, billed 2,713 HCPCS/CPT codes, and received $207,342 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 826 prescription claims across 280 beneficiaries totaling $147,827 in drug costs, led by Jardiance (Empagliflozin). 2022 DME data shows 27 claims. Open Payments data shows 60 records totaling $1,475. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $200,691 and ending at $207,342. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $400,974 to $147,827. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	516	2,525	$200,691
2016	458	2,343	$174,607
2017	448	2,171	$165,165
2018	454	2,829	$208,691
2019	410	2,207	$195,205
2020	312	1,453	$166,592
2021	298	1,350	$165,985
2022	273	1,086	$133,210
2023	170	414	$46,972
2024	660	2,713	$207,342

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	251	1,878	$400,974
2016	241	1,686	$370,948
2017	217	1,438	$364,236
2018	235	1,722	$210,296
2019	230	1,443	$173,872
2020	221	1,390	$129,423
2021	210	1,238	$162,333
2022	229	1,253	$129,022
2023	190	1,010	$114,614
2024	280	826	$147,827

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	228	$18,274
2016	N/R	216	$16,756
2017	N/R	152	$7,542
2018	N/R	161	$7,877
2019	N/R	200	$7,602
2020	N/R	102	$4,545
2021	N/R	32	$1,319
2022	N/R	27	$580
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	174	185	$146
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	228	325	$106
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	175	394	$100
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	264	699	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	146	183	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	55	2,559	$48,040
Farxiga	Dapagliflozin Propanediol	37	2,085	$37,004
Veltassa	Patiromer Calcium Sorbitex	15	803	$18,299
Lokelma	Sodium Zirconium Cyclosilicate	15	926	$12,270
Cinacalcet Hcl	Cinacalcet Hcl	18	1,336	$3,646

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$1,475	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmet Sevimli, MD?

Tedicare shows public-source Medicare data for Ahmet Sevimli, MD (NPI 1912096629), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmet Sevimli, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ahmet Sevimli, MD?

Ahmet Sevimli, MD is linked to FLORIDA KIDNEY AND HYPERTENSION SPECIALISTS PA (billing NPI 1952557860) in the available physician profile data.

Does Ahmet Sevimli, MD have Open Payments data?

Ahmet Sevimli, MD has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.